Dual role for Id2 in chemical carcinogen-induced skin tumorigenesis

Carcinogenesis

Volumn 30, Issue 9, 2009, Pages 1645-1650

  Tokuriki, Atsushi ^a   Iyoda, Tomonori ^b   Inaba, Kayo ^b   Ikuta, Koichi ^b   Fujimoto, Shinji ^c   Kumakiri, Masanobu ^a   Yokota, Yoshifumi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E; INHIBITOR OF DIFFERENTIATION 2; CCND1 PROTEIN, MOUSE; IDB2 PROTEIN, MOUSE; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS CELL; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CANCER; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR; T LYMPHOCYTE;

ANIMALS; CELL PROLIFERATION; CYCLIN D1; INHIBITOR OF DIFFERENTIATION PROTEIN 2; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 70249123824     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp172     Document Type: Article

References (28)

1. Massari,M.E. et al. (2000) Helix-loop-helix proteins: Regulators of transcription in eucaryotic organisms. Mol. Cell. Biol., 20 429-440.
2. Yokota,Y. et al. (2002) Role of Id family proteins in growth control. J. Cell. Physiol., 190, 21-28.
3. Sikder,H.A. et al. (2003) Id proteins in cell growth and tumorigenesis. Cancer Cell, 3, 525-530.
4. Perk,J. et al. (2005) Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer, 5, 603-614.
5. Langlands,K. et al. (2000) Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell carcinoma. Cancer Res., 60, 5929-5933.
6. Lyden,D. et al. (1999) Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature, 401, 670-677.
7. Ciarrocchi,A. et al. (2007) Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS ONE, 2, e1338.
8. Sikder,H. et al. (2003) Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell, 4, 291-299.
9. Girardi,M. et al. (2001) Regulation of cutaneous malignancy by γδ T cells. Science, 294, 605-609.
10. Owens,D.M. et al. (1999) A multihit, multistage model of chemical carcinogenesis. Carcinogenesis, 20, 1837-1844.
11. Yokota,Y. et al. (1999) Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature, 397, 702-706.
12. Lee,H.C. et al. (2002) Seeding of dendritic epidermal T cells in the neonatal skin is reduced in 129 strain of mice. Immunol. Lett. 81, 211-216.
13. Ortner,U. et al. (1996) An improved isolation method for murine migratory cutaneous dendritic cells. J. Immunol. Methods, 193 71-79.
14. Hara-Chikuma,M. et al. (2009) The expression of differentiation markers in aquaporin-3 deficient epidermis. Arch. Dermatol. Res., 301, 245-252.
15. Moll,R. et al. (1982) The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31, 11-24.
16. Hacker,C. et al. (2003) Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol., 4, 380-386.
17. Merad,M. et al. (2008) Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol., 8, 935-947.
18. Woods,G.M. et al. (2005) The skin immune system and the challenge of tumor immunosurveillance. Eur. J. Dermatol., 15, 63-69.
19. Qu,M. et al. (1997) Chemical carcinogenesis and antigens contribute to cutaneous tumor promotion by depleting epidermal Langerhans cells. Carcinogenesis, 18, 1277-1279.
20. Stoitzner,P. et al. (2008) Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J. Immunol., 180, 1991-1998.
21. Marshall,M.S. (1995) Ras target proteins in eukaryotic cells. FASEB J., 9, 1311-1318.
22. Griner,E.M. et al. (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer, 7, 281-294.
23. Robles,A.I. et al. (1998) Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev., 12, 2469-2474.
24. Alao,J.P. (2007) The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol. Cancer, 6, 24.
25. Diehl,J.A. et al. (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev., 11, 957-972.
26. Diehl,J.A. et al. (1998) Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12, 3499-3511.
27. Lin,D.I. et al. (2006) Phosphorylation-dependent ubiquitination of cyclin D1 by the SCFFBx4-aB crystallin complex. Mol. Cell, 24 355-366.
28. Okabe,H. et al. (2006) A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE, 1, e128.